Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.38 |
| ▸ | LPL | P06858 | 6/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632096 | 0.88 | ENPP2 (0.42) | ENPP2HSD17B10LIPGLPLEGFR | |
| SCHEMBL3791071 | 0.83 | ENPP2 (0.45) | ENPP2HSD17B10LIPGLPLEGFR | |
| SCHEMBL28526616 | 0.78 | TYR (0.38) | ENPP2LIPGEGFRMAPTPKM | |
| SCHEMBL17419154 | 0.78 | LIPG (0.39) | LIPGLPLCA2 | |
| SCHEMBL29653353 | 0.78 | ENPP2 (0.45) | ENPP2HSD17B10LIPGLPLSHBG | |
| SCHEMBL6487851 | 0.78 | ENPP2 (0.45) | ENPP2HSD17B10LIPGLPLSHBG | |
| SCHEMBL31164052 | 0.77 | MAPT (0.42) | ENPP2HSD17B10MAPT | |
| SCHEMBL3790270 | 0.77 | PRKCI (0.40) | ENPP2LIPGKDM4EMAPT | |
| SCHEMBL456642 | 0.77 | MAPT (0.42) | ENPP2HSD17B10MAPT | |
| SCHEMBL2295096 | 0.77 | ENPP2 (0.44) | ENPP2HSD17B10LIPGLPLCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085590-B2 | Protecting groups for boronic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2014153041-A1 | PROTECTING GROUPS FOR BORONIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275601-A1 | PROTECTING GROUPS FOR BORONIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ENPP2 1920/4885HSD17B10 1100/4885LIPG 3010/4885 |
| US-20140275601-A1 | PROTECTING GROUPS FOR BORONIC ACIDS | BRS3, CD79B, NR0B2 | ENPP2 3403/4885HSD17B10 1280/4885LIPG 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.